In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Survey Highlights HIV Knowledge Gaps

HIV Misinformation Persists Among Millennials, African Americans

Executive Summary

New options for the treatment and prevention of HIV/AIDs in recent years have not erased lingering stigmas and misinformation about the disease, especially among younger black communities in the US. Advocates hope that greater awareness of “U=U,” or “undetectable equals untransmittable,” can help to address ongoing discrimination and disparities.

You may also be interested in...



Viiv’s Cabotegravir Shows Superiority Over Truvada as PrEP Among Women

ViiV unblinded the Phase III study on positive data, and it plans to pursue approval in H1 2021.

Options, Expertise And Risk Tolerance Needed For Successful Value-Based Contracts

Biohaven Pharmaceuticals developed six different value-based contracting options to support the launch of acute migraine therapy, Nurtec ODT. Despite contract complexity and lingering regulatory risk, payers are aggressively pursuing value-based contracts, leading even small biopharmas to invest in strong health economics capabilities.

Exit Interview: Ken Kaitin On 35 Years At Tufts Center For Study Of Drug Development

At the end of December 2020, Kenneth Kaitin retired as director of the Tufts Center for the Study of Drug Development after 23 years in the role, and 35 years working with the CSDD. Kenneth Getz, previously professor and deputy director of the CSDD, succeeds Kaitin as director in 2021. 

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel